Literature DB >> 19077094

Complete remission of psoriasis following bevacizumab therapy for colon cancer.

A Akman1, E Yilmaz, H Mutlu, M Ozdogan.   

Abstract

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19077094     DOI： 10.1111/j.1365-2230.2008.02991.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


  19 in total

Review 1.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.

Authors:  Andrew J Pellatt; Roger K Wolff; Gabriela Torres-Mejia; Esther M John; Jennifer S Herrick; Abbie Lundgreen; Kathy B Baumgartner; Anna R Giuliano; Lisa M Hines; Laura Fejerman; Richard Cawthon; Martha L Slattery
Journal:  Genes Chromosomes Cancer       Date:  2013-04-30       Impact factor: 5.006

3.  Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.

Authors:  Helia B Schonthaler; Reto Huggenberger; Stefanie K Wculek; Michael Detmar; Erwin F Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

4.  VEGF-Trap decreases CD4+ T cells, Th17 cytokines improving psoriasis-like skin inflammation in KC-Tie2 mice.

Authors:  Doina Diaconu; Yi Fritz; Sean M Dawes; Candace M Loyd; Nicole L Ward
Journal:  J Dermatol Sci       Date:  2013-08-17       Impact factor: 4.563

5.  Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.

Authors:  John R Zibert; Katrin Wallbrecht; Margarete Schön; Lluis M Mir; Grete K Jacobsen; Veronique Trochon-Joseph; Céline Bouquet; Louise S Villadsen; Ruggero Cadossi; Lone Skov; Michael P Schön
Journal:  J Clin Invest       Date:  2010-12-06       Impact factor: 14.808

6.  Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma.

Authors:  D Graceffa; E Maiani; A Pace; F M Solivetti; F Elia; C De Mutiis; C Bonifati
Journal:  Case Rep Rheumatol       Date:  2012-11-29

7.  Role of VEGF receptors in normal and psoriatic human keratinocytes: evidence from irradiation with different UV sources.

Authors:  Jian-Wei Zhu; Xian-Jie Wu; Zhong-Fa Lu; Dan Luo; Sui-Qing Cai; Min Zheng
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

8.  Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis.

Authors:  Tej Pratap Singh; Michael P Schön; Katrin Wallbrecht; Alexandra Gruber-Wackernagel; Xiao-Jing Wang; Peter Wolf
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

Review 9.  Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis.

Authors:  Anja K Weidemann; Ania A Crawshaw; Emily Byrne; Helen S Young
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-09-26

10.  Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer.

Authors:  Ananaya Datta-Mitra; Navdeep K Riar; Siba P Raychaudhuri
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.